b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31225921</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>04</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>05</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1875-9114</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>39</Volume>\n                    <Issue>8</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>08</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Pharmacotherapy</Title>\n                <ISOAbbreviation>Pharmacotherapy</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Evaluation of Severe Myalgia Induced by Continuous-Infusion Bumetanide in Patients with Acute Heart Failure.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>854-860</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1002/phar.2297</ELocationID>\n            <Abstract>\n                <AbstractText Label="STUDY OBJECTIVES">Continuous intravenous (IV) infusion bumetanide has been associated with severe myalgia in case reports, and the package labeling lists a reported incidence of 0.2% for severe myalgia. The primary objective of this study was to quantify the incidence of bumetanide infusion-induced severe myalgia in patients with acute heart failure (AHF). Secondary objectives were to assess a dose-response relationship between bumetanide infusion rate and occurrence of myalgia and to investigate potential risk factors associated with bumetanide-induced myalgia.</AbstractText>\n                <AbstractText Label="DESIGN">Retrospective analysis.</AbstractText>\n                <AbstractText Label="SETTING">Large academic medical center.</AbstractText>\n                <AbstractText Label="PATIENTS">Adults hospitalized with AHF who required bumetanide (\xe2\x89\xa5\xc2\xa00.5\xc2\xa0mg/hr [464 patients]) or furosemide (\xe2\x89\xa5\xc2\xa020\xc2\xa0mg/hr [197 patients]) by continuous IV infusion between September 2015 and May 2017.</AbstractText>\n                <AbstractText Label="MEASUREMENTS AND MAIN RESULTS">The incidence of severe myalgia with IV furosemide infusion was assessed to measure confounding by indication bias. Electronic medical records were used to identify patients exposed to bumetanide 0.25-mg/ml or furosemide 2-mg/ml continuous IV infusions. We defined severe myalgia as a diffuse myalgia with a physician\'s documented suspicion of bumetanide- or furosemide-induced myalgia unresponsive to electrolyte repletion and necessitating a change to alternative diuretics. The incidence of severe myalgia during bumetanide therapy was 5.8%, with the incidence increasing with higher bumetanide infusion rates: 2.6% for an infusion rate \xe2\x89\xa4\xc2\xa01\xc2\xa0mg/hour and 10.3% for a rate &gt;\xc2\xa01\xc2\xa0mg/hour (p=0.0005). In the multivariate logistic regression analysis, a bumetanide infusion rate &gt;\xc2\xa01\xc2\xa0mg/hour was independently associated (odds ratio 4.8, 95% confidence interval 1.94-12.02, p=0.0007) with severe myalgia compared to that with a rate \xe2\x89\xa4\xc2\xa01\xc2\xa0mg/hour. No patients receiving furosemide continuous IV infusion experienced severe myalgia, although infusion rates were lower in potency than bumetanide infusion rates.</AbstractText>\n                <AbstractText Label="CONCLUSION">The incidence of severe myalgia in patients with AHF receiving bumetanide infusion was 5.8%, 29-fold higher than incidence rate listed in the package labeling. Patients receiving infusion rates &gt;\xc2\xa01\xc2\xa0mg/hour were 4-fold more likely to experience bumetanide-induced severe myalgia than those receiving rates \xe2\x89\xa4\xc2\xa01\xc2\xa0mg/hour.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2019 Pharmacotherapy Publications, Inc.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Xiong</LastName>\n                    <ForeName>Lianjie</ForeName>\n                    <Initials>L</Initials>\n                    <Identifier Source="ORCID">0000-0002-0570-8505</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical Sciences, California Health Sciences University College of Pharmacy, Clovis, California.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chinaeke</LastName>\n                    <ForeName>Eric E</ForeName>\n                    <Initials>EE</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>University of South Carolina College of Pharmacy, Columbia, South Carolina.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lu</LastName>\n                    <ForeName>Kevin</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>University of South Carolina College of Pharmacy, Columbia, South Carolina.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lenihan</LastName>\n                    <ForeName>Daniel J</ForeName>\n                    <Initials>DJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Washington University School of Medicine, St. Louis, Missouri.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Merritt</LastName>\n                    <ForeName>Tyler E</ForeName>\n                    <Initials>TE</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Vanderbilt University Medical Center Department of Pharmaceutical Services, Nashville, Tennessee.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cox</LastName>\n                    <ForeName>Zachary L</ForeName>\n                    <Initials>ZL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Vanderbilt University Medical Center Department of Pharmaceutical Services, Nashville, Tennessee.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Lipscomb University College of Pharmacy, Nashville, Tennessee.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>11</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Pharmacotherapy</MedlineTA>\n            <NlmUniqueID>8111305</NlmUniqueID>\n            <ISSNLinking>0277-0008</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D004232">Diuretics</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0Y2S3XUQ5H</RegistryNumber>\n                <NameOfSubstance UI="D002034">Bumetanide</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>7LXU5N7ZO5</RegistryNumber>\n                <NameOfSubstance UI="D005665">Furosemide</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D002034" MajorTopicYN="N">Bumetanide</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004232" MajorTopicYN="N">Diuretics</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005665" MajorTopicYN="N">Furosemide</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D063806" MajorTopicYN="N">Myalgia</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>\n                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>\n                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>\n                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>\n                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">adverse event</Keyword>\n            <Keyword MajorTopicYN="Y">bumetanide</Keyword>\n            <Keyword MajorTopicYN="Y">heart failure</Keyword>\n            <Keyword MajorTopicYN="Y">myalgia</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>5</Month>\n                <Day>6</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31225921</ArticleId>\n            <ArticleId IdType="doi">10.1002/phar.2297</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'